Stents Drug Eluting

This channel includes news and new technology innovations for drug eluting stents (DES). This includes both metallic and bioresorbable drug-eluting stents and related clinical trial data.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting | January 17, 2018 | Dave Fornell

There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or...

Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting | December 13, 2017

December 13, 2017 — Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug...

The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017

November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting,...

News | Stents | November 10, 2017

November 10, 2017 — Cordis, a Cardinal Health company, recently unveiled a comprehensive...

The Xience Sierra stent.
Technology | Stents Drug Eluting | November 09, 2017

November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience...

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017

November 8, 2017 – New results from the HARMONEE Japan/U.S. Registration Trial, reported by in a first report...

Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents
News | Antiplatelet and Anticoagulation Therapies | November 06, 2017

November 6, 2017 —  The first trial to evaluate the safety of...

Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting | November 06, 2017

November 6, 2017 — Elderly patients undergoing...

Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting | November 03, 2017

November 3, 2017 — Biotronik's Orsiro...

Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting | November 01, 2017

November 1, 2017 — OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at...

FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017

October 27, 2017 — CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved...

News | Stents Drug Eluting | October 25, 2017

October 25, 2017 — Elixir Medical Corp. announced it will unveil a new metallic drug-eluting stent (DES) platform at...

Amaranth Medical to Share Bioresorbable Scaffold Data at TCT
News | Stents Bioresorbable | October 25, 2017

October 25, 2017 — Amaranth Medical will provide an update at the annual Transcatheter Cardiovascular Therapeutics (...

Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting | September 01, 2017

September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and...

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies | August 18, 2017

August 18, 2017 — Medtronic plc announced a global randomized...

Overlay Init